177 related articles for article (PubMed ID: 20145144)
1. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Zander SA; Kersbergen A; van der Burg E; de Water N; van Tellingen O; Gunnarsdottir S; Jaspers JE; Pajic M; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2010 Feb; 70(4):1700-10. PubMed ID: 20145144
[TBL] [Abstract][Full Text] [Related]
2. EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Zander SA; Sol W; Greenberger L; Zhang Y; van Tellingen O; Jonkers J; Borst P; Rottenberg S
PLoS One; 2012; 7(9):e45248. PubMed ID: 23028879
[TBL] [Abstract][Full Text] [Related]
3. Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.
Zander SA; Kersbergen A; Sol W; Gonggrijp M; van de Wetering K; Jonkers J; Borst P; Rottenberg S
Cancer Prev Res (Phila); 2012 Aug; 5(8):1053-60. PubMed ID: 22767648
[TBL] [Abstract][Full Text] [Related]
4. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Jaspers JE; Kersbergen A; Boon U; Sol W; van Deemter L; Zander SA; Drost R; Wientjens E; Ji J; Aly A; Doroshow JH; Cranston A; Martin NM; Lau A; O'Connor MJ; Ganesan S; Borst P; Jonkers J; Rottenberg S
Cancer Discov; 2013 Jan; 3(1):68-81. PubMed ID: 23103855
[TBL] [Abstract][Full Text] [Related]
5. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Rottenberg S; Jaspers JE; Kersbergen A; van der Burg E; Nygren AO; Zander SA; Derksen PW; de Bruin M; Zevenhoven J; Lau A; Boulter R; Cranston A; O'Connor MJ; Martin NM; Borst P; Jonkers J
Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17079-84. PubMed ID: 18971340
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
8. Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Henneman L; van Miltenburg MH; Michalak EM; Braumuller TM; Jaspers JE; Drenth AP; de Korte-Grimmerink R; Gogola E; Szuhai K; Schlicker A; Bin Ali R; Pritchard C; Huijbers IJ; Berns A; Rottenberg S; Jonkers J
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8409-14. PubMed ID: 26100884
[TBL] [Abstract][Full Text] [Related]
9. ABCG2 expression, function, and promoter methylation in human multiple myeloma.
Turner JG; Gump JL; Zhang C; Cook JM; Marchion D; Hazlehurst L; Munster P; Schell MJ; Dalton WS; Sullivan DM
Blood; 2006 Dec; 108(12):3881-9. PubMed ID: 16917002
[TBL] [Abstract][Full Text] [Related]
10. BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.
Jaspers JE; Sol W; Kersbergen A; Schlicker A; Guyader C; Xu G; Wessels L; Borst P; Jonkers J; Rottenberg S
Cancer Res; 2015 Feb; 75(4):732-41. PubMed ID: 25511378
[TBL] [Abstract][Full Text] [Related]
11. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
12. Novel ABCG2 Antagonists Reverse Topotecan-Mediated Chemotherapeutic Resistance in Ovarian Carcinoma Xenografts.
Ricci JW; Lovato DM; Severns V; Sklar LA; Larson RS
Mol Cancer Ther; 2016 Dec; 15(12):2853-2862. PubMed ID: 27671528
[TBL] [Abstract][Full Text] [Related]
13. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
Rottenberg S; Nygren AO; Pajic M; van Leeuwen FW; van der Heijden I; van de Wetering K; Liu X; de Visser KE; Gilhuijs KG; van Tellingen O; Schouten JP; Jonkers J; Borst P
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):12117-22. PubMed ID: 17626183
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
[TBL] [Abstract][Full Text] [Related]
15. ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.
Balmus G; Pilger D; Coates J; Demir M; Sczaniecka-Clift M; Barros AC; Woods M; Fu B; Yang F; Chen E; Ostermaier M; Stankovic T; Ponstingl H; Herzog M; Yusa K; Martinez FM; Durant ST; Galanty Y; Beli P; Adams DJ; Bradley A; Metzakopian E; Forment JV; Jackson SP
Nat Commun; 2019 Jan; 10(1):87. PubMed ID: 30622252
[TBL] [Abstract][Full Text] [Related]
16. The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
To C; Kim EH; Royce DB; Williams CR; Collins RM; Risingsong R; Sporn MB; Liby KT
Cancer Prev Res (Phila); 2014 Jul; 7(7):698-707. PubMed ID: 24817481
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.
Houghton PJ; Germain GS; Harwood FC; Schuetz JD; Stewart CF; Buchdunger E; Traxler P
Cancer Res; 2004 Apr; 64(7):2333-7. PubMed ID: 15059881
[TBL] [Abstract][Full Text] [Related]
18. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
[TBL] [Abstract][Full Text] [Related]
19. Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Saraiya B; Gounder M; Dutta J; Saleem A; Collazo C; Zimmerman L; Nazar A; Gharibo M; Schaar D; Lin Y; Shih W; Aisner J; Strair RK; Rubin EH
Anticancer Drugs; 2008 Apr; 19(4):411-20. PubMed ID: 18454051
[TBL] [Abstract][Full Text] [Related]
20. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Poller B; Wagenaar E; Tang SC; Schinkel AH
Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
